2017 Bladder Cancer Canada/CUOG:

“Combination of radiation and TIM-3 blockade as a new strategy to improve bladder-organ preservation treatment in muscle-invasive bladder cancer”

    • Dr. Ayoub
    • Supervisor: Dr. Kassouf
    • $10,000

“Development of ultrasound-guided orthotopic patient-derived bladder cancer xenografts for precision oncology”

    • Dr. Contreras-Sanz
    • Supervisor: Dr. Black
    • $10,000

“The RESECT Trial: A vanguard randomized trial to compare re-resction of high grade T1 bladder urothelial carcinoma to no re-resection for improving progression free survival”

    • Dr. Klassen
    • Supervisor: Dr. Kulkarni
    • $10,000

“Immune checkpoint inhibitors in non-muscle invasive bladder cancer: evaluating the transcriptome of patient specimens to identify new targets and predict efficacy”

    • Dr. Chandrasekar
    • Supervisor: Dr. Zlotta
    • $10,000

“Setting patient-adjusted performance standards in robotic-assisted radical prostatectomy”

    • Dr. Goldberg
    • Supervisor: Dr. Fleshner
    • $10,000


“Magnetically-actuated drug delivery device for minimally invasive treatment of localized prostate cancer”

    • Dr. Tan
    • Sponsor: Dr. So
    • $10,000

“Genomic rearrangements of the androgen receptor (AR) and resistance to first-line treatment with AR pathway inhibitors in castration-resistant prostate cancer”

    • Dr. Khalaf
    • Sponsor: Dr. Chi
    • $10,000

“Role of IKK╬ż (epsilon) in the development of castration-resistant prostate cancer and disease progression”

    • Dr. Gilbert
    • Sponsor: Dr. Saad
    • $10,000

2017 BAYER/CUOG Awards:

“Correlating serum steroid profiles and total circulating androgenic activity to investigate castration resistance in prostate cancer”

    • Dr. Clermont
    • Sponsor: Dr. Pouliot
    • $15,000

2017 MERCK Awards:

“Incidence of mismatch repair gene mutations in patients with upper tract urothelial carcinoma”

    • Dr. Goldenberg
    • Sponsor: D. Finelli
    • $10,000

“Combination of PD-1 Blockade and OX40 stimulation for bladder cancer treatment”

    • Dr. Gaignier
    • Sponsor: Dr. Fradet
    • $10,000


“Evaluation of sphingolipid cermide and intracellular signaling markers of prostate cancer in patients with intermediate-risk prostate cancer receiving a hypofractionation regimen treatment combined with a high dose rate brachytherapy boost.”

  • Dr. Quinn
  • Sponsor: Dr. Vigneault
  • $10,000